Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers

(2014) Kaku Saito et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines

(2013) D. Ransom et al.   ANNALS OF ONCOLOGY

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis

(2013) Yu Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pralatrexate Pharmacology and Clinical Development

(2013) E. Marchi et al.   CLINICAL CANCER RESEARCH

Asbestos and the lung in the 21st century: an update

(2013) Silvie Prazakova et al.   Clinical Respiratory Journal

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2013) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

“One Marker Does Not Fit All”: Additional Translational and Validation Studies Are Needed to Identify Faithful Predictors of Pemetrexed Activity in Mesothelioma

(2013) Elisa Giovannetti et al.   Journal of Thoracic Oncology

Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non–Small-Cell Lung Cancer: Implications for Therapy

(2013) Martin K.H. Maus et al.   Journal of Thoracic Oncology

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

(2013) Yasuhide Yamada et al.   LANCET ONCOLOGY

Uracil-DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed

(2013) L. D. Weeks et al.   MOLECULAR CANCER THERAPEUTICS

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

(2012) T Doi et al.   BRITISH JOURNAL OF CANCER

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

(2012) Michael S. Gordon et al.   INVESTIGATIONAL NEW DRUGS

Discovery of a Novel Class of Potent Human Deoxyuridine Triphosphatase Inhibitors Remarkably Enhancing the Antitumor Activity of Thymidylate Synthase Inhibitors

(2012) Seiji Miyahara et al.   JOURNAL OF MEDICINAL CHEMISTRY

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

(2012) Daniel C. Christoph et al.   Journal of Thoracic Oncology

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

(2012) Takayuki Yoshino et al.   LANCET ONCOLOGY

The DNA damage response and cancer therapy

(2012) Christopher J. Lord et al.   NATURE

Molecular prescreening to select patient population in early clinical trials

(2012) Jordi Rodón et al.   Nature Reviews Clinical Oncology

Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair

(2012) A D Bulgar et al.   Cell Death & Disease

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients

(2011) J. Cassidy et al.   ANNALS OF ONCOLOGY

Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells

(2011) A. M. Huehls et al.   CANCER RESEARCH

Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

(2011) P. A. Zucali et al.   CLINICAL CANCER RESEARCH

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

(2011) Jong-Mu Sun et al.   Journal of Thoracic Oncology

Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase-Targeted Therapies in Non-Small Cell Lung Cancer

(2011) P. M. Wilson et al.   MOLECULAR CANCER THERAPEUTICS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The European Medicines Agency Review of Tegafur/Gimeracil/Oteracil (Teysuno ) for the Treatment of Advanced Gastric Cancer When Given in Combination with Cisplatin: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use (CHMP)

(2011) P. Matt et al.   ONCOLOGIST

TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials

(2011) P P Grimminger et al.   PHARMACOGENOMICS JOURNAL

Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil

(2011) Liyi Geng et al.   PLoS One

Small-Molecule Inhibitors of APE1 DNA Repair Function: An Overview

(2011) Rasha I. Al-Safi et al.   Current Molecular Pharmacology

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

(2010) Peter M. Wilson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pemetrexed Indirectly Activates the Metabolic Kinase AMPK in Human Carcinomas

(2010) S. B. Rothbart et al.   CANCER RESEARCH

Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary

(2010) S. M. Malik et al.   CLINICAL CANCER RESEARCH

Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy

(2010) Luisella Righi et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

(2010) M. H. Cohen et al.   ONCOLOGIST

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer

(2009) M. G. Fakih et al.   CLINICAL CANCER RESEARCH

Raltitrexed: optimism and reality

(2009) Kenneth S Wilson et al.   Expert Opinion on Drug Metabolism & Toxicology

S-1: a promising new oral fluoropyrimidine derivative

(2009) Muhammad Wasif Saif et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells

(2009) William Fazzone et al.   INTERNATIONAL JOURNAL OF CANCER

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

(2009) Daniel Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Impairment of APE1 Function Enhances Cellular Sensitivity to Clinically Relevant Alkylators and Antimetabolites

(2009) D. R. McNeill et al.   MOLECULAR CANCER RESEARCH

Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance

(2009) R. Humeniuk et al.   MOLECULAR CANCER THERAPEUTICS

A comprehensive catalogue of somatic mutations from a human cancer genome

(2009) Erin D. Pleasance et al.   NATURE

Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

(2009) M. H. Cohen et al.   ONCOLOGIST

Identification and Characterization of Inhibitors of Human Apurinic/apyrimidinic Endonuclease APE1

(2009) Anton Simeonov et al.   PLoS One

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?

(2008) J. L. Yen-Revollo et al.   CLINICAL CANCER RESEARCH

Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies

(2008) Li-Xin Qiu et al.   INTERNATIONAL JOURNAL OF CANCER

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Updated Results From the BICC-C Study

(2008) Charles S. Fuchs et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer

(2008) A Kawahara et al.   JOURNAL OF CLINICAL PATHOLOGY

Novel opportunities for thymidylate metabolism as a therapeutic target

(2008) P. M. Wilson et al.   MOLECULAR CANCER THERAPEUTICS

The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier

(2008) R. Zhao et al.   MOLECULAR PHARMACOLOGY

Advances in the systemic therapy of malignant pleural mesothelioma

(2008) Dean A Fennell et al.   Nature clinical practice. Oncology